SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Table 12 Change in glycosylated haemoglobin in individual studies

Study	Glycosylated haemoglobin (%)			P value	P value between groups
	Group	Baseline	Study completion
Kuchay et al[11]	Empagliflozin	9.0 (1.0)	7.2 (0.6)	< 0.001	0.88
	Control	9.1 (1.4)	7.1 (0.9)	< 0.0001
Ito et al[12]	Ipragliflozin	8.5 (1.5)	7.6 (1.0)	< 0.05	0.522
	Pioglitazone	8.3 (1.4)	7.1 (0.9)	< 0.05
Shibuya et al[13]	Luseogliflozin	7.8 (7.2, 7.9)	6.5 (6.4, 7.0)	0.002	0.023
	Metformin	7.4 (6.9, 7.7)	7.3 (6.7, 7.6)	0.362
Eriksson et al[14]	Placebo	7.4 (0.8)	-0.1 (0.4)1	-	-
	Omega-3 CA	7.4 (0.7)	+0.1 (0.4)1	-	Non-significant2
	Dapagliflozin	7.4 (0.6)	-0.6 (0.7)1	-	< 0.052
	O + D	7.5 (0.8)	-0.5 (0.5)1	-	Non-significant2
Ohki et al[15]	Ipragliflozin	8.4 (7.8-8.9)	7.6 (6.9-8.2)	< 0.01	-
Seko et al[16]	SGLT-2 inhibitor	6.7 (0.1)	6.5 (0.1)	0.055	Non-significant
	Sitagliptin	7.0 (0.3)	6.9 (0.3)	0.331
Sumida et al[18]	Luseogliflozin	7.3 (0.7)	7.0 (0.7)	0.002	-

¹Change from baseline.

²Compared to placebo.

CA: Carboxylic acid; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.